(AOF) – Theranexus (+11.49% to 1.30 euros) is up sharply after announcing “very encouraging” intermediate results of effectiveness and tolerance after 12 months of treatment in the phase 1 study/ 2 of Batten-1 in Batten disease (CLN3), during the International Congress “NCL2023” on Neuronal Ceroid Lipofuscinoses which takes place in Hamburg (Germany) from September 26 to 30, 2023. The presentation of the results of effectiveness and tolerance at 12 months will be put online on September 29 after trading.
“We are very happy with these results at 12 months which reinforce and complement the first results at 6 months,” declares Mathieu Charvériat, Managing Director of Theranexus. “The reduction in biomarker levels confirms the effect of Batten-1 on neuronal death, and the clinical course did not worsen. These consistent results represent an important validation of the mechanism of action, and demonstrate a strong therapeutic potential of Batten-1 in Batten disease (CLN3)”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.